The Zhitong Finance App learned that China's traditional Chinese medicine (00570) resumed trading by more than 24%. As of press release, it had risen 24.49% to HK$4.27, with a turnover of HK$125 million.
According to the news, China Traditional Chinese Medicine announced that Sinopharm Group proposed to privatize Chinese medicines at a cash price of HK$4.6 per share through planned arrangements. Sinopharm's price is a 34.11% premium over the latest closing price of Chinese medicines. The total cost of Sinopharm's privatization proposal is about HK$15.45 billion.